Investor Newsletter

Issue 08 2021

MicroPort®

MicroPort® Announces 2021 Interim Results

MicroPort Scientific Corporation (hereafter referred to as the "Company" or "MicroPort®", stock code: 00853) announced on August 30 the interim results of the Company and its subsidiaries (hereafter referred to as the "Group") for the six months ended June 30, 2021 (hereafter referred to as the "Reporting Period"). In the first half of 2021, as most countries and regions gradually entered the stage of normalized epidemic prevention and control, the Group actively promoted the development of its businesses in China and overseas, expedited the promotion of its global business layout, and maintained a leading position in terms of marketing and sales in its core businesses.

In the first half of 2021, the Group achieved revenue of US$384.6 million, representing an increase of 17.7% as compared to the corresponding period of last year. In particular, the heart valve business, the neurovascular devices business, and the endovascular and peripheral vascular devices business, continued their strong growth trend, with revenue significantly increased by 121.8%, 114.5% and 68.6% respectively on year-on-year basis.

Dr. Zhaohua Chang, Chairman and CEO of MicroPort®, said, "MicroPort®, as a leading innovative high-end medical device conglomerate, will fulfill its mission and social responsibility by actively developing diversified product lines and integrated solutions through continuous innovation, and aims to continuously bring its innovations, technologies and services to millions of global patients and become a patient oriented global leading enterprise in high technology medical segments represented by minimal invasive and other emerging medical markets."

Endovastec™ Announces 2021 Interim Results

MicroPort Endovastec™ (hereafter referred to as the "Company" or "Endovastec™", stock code: 688016.SH), a subsidiary of MicroPort Scientific Corporation (Stock Code: 00853.HK) announced on August 26th the interim results of the Company and its subsidiaries (hereafter referred to as the "Group") for the six months ended June 30, 2021 (hereafter referred to as the "Reporting Period"). In the first half of 2021, the Group achieved revenue of RMB362 million, representing an increase of 68.62% as compared to the corresponding period of last year, with the gross profit margin increased significantly by 53.23% and earnings per share increased by 53.89% over the same period last year.

Mr. Zhuqing, President of Endovastec™, said, "Endovastec™ focuses on high-quality development, actively promotes and builds group operation of the company, and devotes greater effort to the globalization of innovative products. Our listed products have been growing fast at home and abroad, product pipeline in both aortic and peripheral intervention have been comprehensively planned. Besides, we positively fulfill social responsibilities. In the future, we will maintain R&D innovation and forward-looking strategic layout, continue work toward 'the world's leading high-tech medical group', and provide trustworthy and universal access to state-of-art total solutions to treat aortic and peripheral diseases."

MicroPort

CardioFlow Medtech
Announces 2021 Interim Results

MicroPort CardioFlow Medtech Corporation (hereafter referred to as the "Company" or "CardioFlow", Stock code: 02160.HK), a subsidiary of MicroPort Scientific Corporation (hereafter referred to as the "MicroPort®", Stock code: 00853.HK) announced on August 29, 2021 the interim results of the Company and its subsidiaries for the six months ended June 30, 2021 (hereafter referred to as the "Reporting Period"). In the Reporting Period, the Group recorded revenue of RMB86.2 million, representing an increase of 121.8% as compared to the corresponding period of last year, with the gross profit margin increased significantly by 11 percentage points to 55.1%.

"Relying on VitaFlow®'s unique product design and excellent clinical performance, and thanks to the continuous efforts of our marketing and sales team, the Company further expanded hospital coverage and achieved a sustained high revenue growth. With the approval of VitaFlow Liberty™, we have every confidence in maintaining high growth, increasing rapidly the hospital coverage and product sales and taking the leading position in domestic market. In the future, we will keep adhering to the Company's philosophy of "focus, innovation, and globalization" to provide trustworthy and universal access to state-of-the-art total solutions to treat structural heart diseases." said Mr. Chen Guoming, the executive director and President of CardioFlow.

First Motorized Retrievable Transcatheter Aortic Valve (TAVI) System - VitaFlow Liberty™ received approval for marketing in China

On 31st August 2021, MicroPort CardioFlow Medtech Corporation (CardioFlow Medtech), a subsidiary of MicroPort Scientific Corporation, announced that its transcatheter aortic valve system – the VitaFlow Liberty™ Transcatheter Aortic Valve and Retrievable Delivery System (VitaFlow Liberty™) – has received approval for marketing by China's National Medical Products Administration (NMPA). As the first motorized retrievable transcatheter aortic valve system approved for marketing, VitaFlow Liberty™ leads as the first motorized retrievable system in the Transcatheter Aortic Valve Implantation (TAVI) market.

Guoming Chen, Executive Director and President of CardioFlow Medtech, said, "CardioFlow Medtech has an extensive product portfolio in the field of transcatheter aortic therapy, providing clinicians with comprehensive transcatheter aortic therapy solutions. The upgrade of VitaFlow Liberty™ lies in the unique features provided by the innovative delivery system, which further improve the surgical experience. We believe that our ability to continuously innovate will ensure the core competitiveness of our future products for the benefit of more patients."

Dr. Qiyi Luo, Chief Technology Officer of MicroPort® and Chairman of the Board of Directors of CardioFlow Medtech, commented, "Within years of the launch of VitaFlow®, the product is already used in more than 220 heart centers across China, allowing MicroPort® to become a key player in the Chinese heart valve market. We are now more confident and motivated to accelerate our development of medical devices for valvular heart disease. With the market launch of the VitaFlow Liberty™ System, CardioFlow Medtech will be able to better meet clinical needs, and provide better clinical outcomes."

MicroPort™

Firehawk®, Foxtrot® NC and Foxtrot® Pro PTCA Balloon Catheters Receive Approval in Turkmenistan

Shanghai MicroPort Medical (Group) Co., Ltd. (MicroPort®) has recently received registration approval from the Turkmenistan Ministry of Health and Medical Industry for three of its proprietary products: the Firehawk® Rapamycin Target Eluting Coronary Stent System (Firehawk®), Foxtrot® NC PTCA Balloon Catheter (Foxtrot® NC), and Foxtrot® Pro PTCA Coronary Balloon Catheter (Foxtrot® Pro).

The approval of these three MicroPort® products in Turkmenistan shows industry recognition of MicroPort® for its outstanding product portfolio in the field of coronary intervention, further expanding the company's global presence. In the future, MicroPort® will continue to pursue an innovative, people-centered culture to provide patients and physicians around the world with higher-quality, innovative high-end medical devices and integrated solutions.



MicroPort® NeuroTech Completes First Implantation of NUMEN® Coil Embolization System in Chile, Marking Their Debut in an Overseas Market

The NUMEN® Coil Embolization System (NUMEN®), developed by Shanghai MicroPort NeuroTech Co., Ltd. (MicroPort® NeuroTech) has been implanted in a patient in Chile, marking not only the first implantation of NUMEN® in an overseas market, but also the debut of MicroPort® NeuroTech products outside of China.

Zhiyong Xie, President of MicroPort® NeuroTech, commented, “Stroke has been a serious threat to the health of human beings worldwide due to its high incapacitation and mortality rates. Coil embolization is a mainstream treatment option for stroke. The first implantation of NUMEN® in an overseas market demonstrates the recognition of MicroPort® NeuroTech products by doctors abroad.”

MicroPort

MSC Completes First Patient Enrollment for Multicenter Post-Marketing Clinical Study 'China Pace'

The first patient enrollment for the 'China Pace' post-marketing clinic study on the Rega® Family Implantable Pacemakers, developed by MicroPort Soaring CRM (Shanghai) Co., Ltd. ('MSC'), was recently completed. The study, led by the First Affiliated Hospital of Dalian Medical University, is expected to carry out a one-year follow-up of nearly 1,000 subjects in 40 clinical centers across China, with the aim of evaluating the safety and efficacy of the Rega® Family Implantable Pacemakers in clinical practices, providing a solid basis for future research and development.

Following the completion of patient enrollment, Xiaoming Zhu, General Manager of MSC, stated, "We would like to take this opportunity to strengthen our cooperation with clinical centers and doctors in China and to promote state-of-the-art technological development and manufacturing in the field of cardiac rhythm management by considering the clinical needs of Chinese patients and doctors, so as to provide more inclusive and accessible total medical solutions for the treatment of cardiac rhythm diseases."

MicroPort

上海环科环境认证有限公司
Shanghai Huanke Environmental Certification Co., Ltd.

能源管理体系认证证书

兹证明

上海微创心脉医疗科技（集团）股份有限公司

（统一社会信用代码：91310115051256532 6）

（注册地址：上海市康新公路3399弄1号）

（生产经营地址：上海市浦东新区康新公路3399弄25号9层和5层、
上海市浦东新区康新公路3399弄1号楼、上海市浦东新区芙蓉花路388号）

建立的能源管理体系符合标准：

GB/T 23331-2020 / ISO 50001:2018 能源管理体系 要求及使用指南
SEC/En2.10.05.011-2019 能源管理体系 医疗仪器及器械制造企业认证要求

通过认证范围如下：

分支型主动脉覆膜支架及输送系统、术中支架系统、外周血管支架系统、分叉型大动脉覆膜支架及输送系统、外周球囊扩张导管、腹主动脉覆膜支架及输送系统、分叉型覆膜支架及输送系统、球囊扩张导管、直管型覆膜支架及输送系统、药物球囊扩张导管的设计开发、生产和相关管理活动过程中涉及的能源采购、转换、输配、使用及余热回收利用过程的能源管理及节能技术应用活动

（获证组织的能源绩效及边界见标有相同证书注册号的证书附件，证书附件是本证书组成部分。获证组织须定期接受监督审核并经审核合格后此证书方继续有效。）

（该证书为多地址证书，其他具体地址在后续页上列出。）

注册号：098 21 En1 026 R0 M
发证日期：2021年07月15日
有效期至：2024年07月14日

签发人：

CNAS MANAGEMENT SYSTEM CNAS C090-M

扫描二维码验证本证书信息，有疑问请立即联系本机构。
本证书信息可在国家认证认可监督管理委员会官方网址(www.cnca.gov.cn)上查询。

上海市钦州路508号 200233　电话：86-21-64085119　传真：86-21-64081189　电子信箱：sec@sacs.sh.cn

Endovastec™ Receives ISO 50001 Energy Management System Certificate

Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. (Endovastec™) has obtained the ISO 50001:2018 Energy Management System Certificate after passing the assessment by the Conformity Assessment Certification Body. To date, Endovastec™ has developed an increasingly comprehensive management system after having passed a series of system certifications including for quality management, environmental management, occupational health and safety management, brand cultivation management, and intellectual property management, as well as the CNAS (China National Accreditation Service for Conformity Assessment) laboratory certification.

Over the years, Endovastec™ has been committed to energy conservation, emission reduction, and energy system management. The company has set up an internal review team and carried out a series of work, including compiling documents for the energy management system, standardizing compliance to energy laws and regulations, organizing staff training on energy conservation, and carrying out internal audits and management reviews, to ensure that all the efforts on energy management system have been efficiently promoted.

MicroPort

MicroPort® EP OptimAblate™ Tubing Set Receives NMPA Marketing Approval

Shanghai MicroPort EP MedTech Co., Ltd., (MicroPort® EP), has recently received marketing approval from China's National Medical Products Administration (NMPA) for its self-developed OptimAblate™ Tubing Set.

The OptimAblate™ Tubing set is a disposable infusion tube that can be used in conjunction with MicroPort® EP's OptimAblate™ Irrigation Pump to accurately infuse saline and other solutions at controlled flow rates into the distal end of irrigation catheters to cool local tissues, minimize the risk of thrombosis, and reduce complications of the procedure. MicroPort® EP's OptimAblate™ Irrigation Pump and several saline irrigation catheters have already received marketing approval, so the approval of the OptimAblate™ Tubing Set further adds to MicroPort® EP's diverse product line.

MicroPort EP and Stereotaxis Collaborate to Advance Innovation and Adoption of Robotic Electrophysiology in China

Shanghai MicroPort EP MedTech Co., Ltd (MicroPort EP) and Stereotaxis (NYSE: STXS) today announced a broad collaboration to advance technology innovation and commercial adoption of robotics in electrophysiology in China.

The agreement brings together MicroPort EP's commercial and product leadership in China's electrophysiology market with Stereotaxis' advanced Robotic Magnetic Navigation technology. As part of the collaboration, MicroPort EP will become the exclusive distributor of Robotic Magnetic Navigation technology for electrophysiology in China.

"Stereotaxis and MicroPort EP are delighted to enter into this strategic collaboration and are confident it will benefit both companies along with the electrophysiologists and arrhythmia patients we serve," said David Fischel, CEO of Stereotaxis and Dr.Yiyong Sun, President of MicroPort EP. "We look forward to providing China's electrophysiology community with highly innovative and differentiated products that leverage Robotic Magnetic Navigation technology. This will both strengthen the importance of robotics and reinforce the key role of MicroPort EP in this rapidly growing and underserved market."

MicroPort

Investor Newsletter

Issue 08 2021

MicroPort®

For more information, please contact:

Martin Sun
Chief Financial Officer
MicroPort Scientific Corporation
Tel: (86)(21) 38954600
Email: ir@microport.com

Leanne Li
Board Secretary & VP of Securities Affairs
MicroPort Scientific Corporation
Tel: (86)(21) 38954600
Email: ir@microport.com